Work

pKDR/KDR ratio predicts response in a phase I/II pharmacodynamic study of erlotinib and bevacizumab for recurrent or metastatic head and neck cancer (HNC)

Year: 2007

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2007.25.18_suppl.6021

Authors: T. Y. Seiwert, D. W. Davis, D. Yan, A. M. Mauer, T. Karrison, M. Kozloff, A. Dekker, S. J. Wong, E. E. Vokes, E. E. Cohen

Institutions: Medical College of Wisconsin, University of Chicago

Language: English

Topic: Head and Neck Cancer Studies

Subfield: Otorhinolaryngology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2608997859

Cites:

Cited by: 12

Related to: 10